Resistance
6 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI) (NCT07241403) | Second Affiliated Hospital of Nanchang University | 2018-01-01 |
| Relationship of Viral Resistance Development to CD4 Monitoring Alone or With Viral Load Monitoring (NCT00434070) | National Institute of Allergy and Infectious Diseases (NIAID) | 2007-02-07 |
Track Resistance automatically
Every clearance here is in the API, with alerts when new ones post.